A NEW FRONTIER
Tune Therapeutics is pioneering the creation of epi-therapeutic medicines.
The vast majority of human disease is governed by the epigenome, the subtle machinery that controls the volume of gene expression in cells. Traditional genetic medicines have long focused on protein-coding gene sequences, which constitute only 2% of the human genome. By exploring the other 98% that regulates these genes, we are discovering novel targets that are invisible or inaccessible to prior approaches.
Genetic tuning enables us to control expression levels across multiple genes simultaneously, by affecting the packing and accessibility of cellular DNA.
OUR APPROACH
Unlike genome editing, our proprietary TEMPO platform dials the volume of gene expression up or down towards healthy levels, without breaking or permanently rewriting DNA – and it can do this in multiple genes at once (multiplexing). This allows us to change cell fate and function at will, unlocking the ability to reverse pathways of cancer, genetic disease and aging.
Our approach effectively expands the potential reach of genetic medicine – from targeting a limited range of rare conditions, to overcoming thousands of complex and chronic diseases that currently have no curative treatment.
OUR TEAM
Tune is driven by leaders with deep expertise in the fields of gene and cell therapy, genome editing, and epigenetics. In breaking free from the limitations of traditional genetic medicine, we are developing solutions for even the most challenging and intractable diseases – and building the capacity to transform human health and medicine.
Matt Kane
Chief Executive Officer
READ BIO
Akira Matsuno
Co-Founder, President and Chief Financial Officer
READ BIO
Charles A. Gersbach, Ph.D.
Co-Founder, Acting Chief Scientific Officer
READ BIO
Heidi Zhang, Ph.D.
Executive Vice President, Technical Operations
READ BIO
Blythe Sather, Ph.D.
Vice President, Head of Research
READ BIO
Fyodor Urnov, Ph.D.
Co-Founder, Scientific Advisory Board
READ BIO
Matt Kane
Chief Executive Officer
READ BIO
Charles A. Gersbach, Ph.D.
Co-Founder, Acting Chief Scientific Officer
READ BIO
Ali Behbahani, M.D.
New Enterprise Associates
READ BIO
Dan McHugh
Emerson Collective
READ BIO
NEWS
12/02/2021
Tune Therapeutics Launches with Pioneering Epigenomic Control Platform to Master Gene Networks, Treat Broad Range of Diseases
READ MOREOPENINGS
Click position title to learn more. Email careers@tunetx.com to apply.
We are looking for someone with a deep immunology background who can think creatively and efficiently to help bring our remarkable epi-genetic editing technology quickly to the clinic.
We are looking for a leader of viral delivery development to help realize the promise of epigenetic programming.
We are looking for a Head of Product Development to lead product characterization and method development team within Technical Operations.
We are looking for the Head of Quality who will establish and ensure compliance with Quality requirements, global regulatory and industry standards, internal standard operating procedures (SOPs), and federal regulations.
We are looking for someone to deliver the look and feel of the facilities and to establish the necessary contracts and processes to operate the facilities.
We are looking for someone to serve as executive assistant to the CEO and manage the administration team.
